![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Received for publication
November 10, 2005
Accepted
March 7, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). Ischemic stroke occurs in 60 to 70% of all forms of stroke patients (Feng, 1999; Silvestrelli et al., 2002; Mahajan et al., 2004).
Ischemic stroke is initiated by a transient or permanent reduction in cerebral blood flow (CBF) that is restricted to the territory of major brain artery, such as the occlusion of middle cerebral artery (MCAO). MCAO impairs irrigation of focal brain areas, which show gradual reductions of CBF from the periphery to the core of the MCA territory (Bolander et al., 1989). The development of ischemic brain damage depends on the reduction of CBF below critical threshold level (Memezawa et al., 1992,Memezawa et al., 1992; Takagi et al., 1995). Then, the decrease of CBF in ischemic regions may result in an energy failure and further lead to an activation of the toxic intracellular pathway (Jorgensen and Diemer, 1982; Dirnagl et al., 1999; Hou and MacManus, 2002). The infarct volume is also dependent on the duration of ischemia (Soriano et al., 1997). Therefore, the severity of ischemia has two components: degree of CBF reduction and duration of the ischemic episode.
Potassium 2-(1-hydroxypentyl)-benzoate (dl-PHPB), derived from 3-n-butylphthalide (dl-NBP), is a newly synthesized compound that is under development as a therapeutic drug for cerebral ischemia (Yang et al., 2002). As reported, dl-NBP is a primary naphtha component from seeds of Apium graveolens Linn. The phase 3 clinical trial of dl-NBP has been completed, and it was approved by the State Food and Drug Administration of China at the end of 2002 as a new drug for treatment of ischemic stroke in clinic. Many basic and clinic studies have proved that dl-NBP is a potentially beneficial and promising drug for treatment of ischemic stroke with multiple actions that affect some pathophysiological processes, such as improving microcirculation of rat brain, inhibition of platelet aggregation, regulation of energy metabolism, inhibition of ischemia-induced oxidative damage, and neuron apoptosis (Chong and Feng, 1997; Yan et al., 1998; Xu and Feng, 2000, 2001; Dong and Feng, 2002). However, dl-NBP is difficult to use intravenously because of its hydrophobicity. Thus, dl-NBP is limited to use in the clinic for serious patients of ischemic stroke. Therefore, dl-PHPB was designed as a predrug of dl-NBP. The properties of dl-PHPB have been greatly improved. In addition, in our previous research, it was found that dl-PHPB could quickly convert to dl-NBP in vitro and in vivo (given to rat orally or intravenously). Recently, it was also found that dl-PHPB could inhibit platelet aggregation ex vivo and reduce thrombus formation in the arteriovenous shunt model in vivo (Zhang et al., 2004). In the present study, the effects of dl-PHPB on CBF, infarct volume, and neurological function were investigated in a rat model of transient focal cerebral ischemia.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
dl-PHPB and dl-NBP were offered by the Department of Synthetic Pharmaceutical Chemistry of our institute with a purity of 99.9%. The chemical structures of these compounds are shown in Fig. 1. According to the molecular weight of two compounds, doses of dl-PHPB (1.3, 3.9, and 12.9 mg/kg) used to treat intravenously were equimolar to the doses of dl-NBP (1, 3, and 10 mg/kg), respectively. dl-PHPB was dissolved in 0.9% saline. dl-NBP was dissolved in component solvent (PEG400/H2O, 1:3) (i.v.).
|
The principles and technical details of laser-Doppler flowmetry (LDF) have been described elsewhere (Dirnagl et al., 1989). For the continuous measurement of local regional CBF (rCBF), the rat was fixed in a stereotaxic frame. The skull was exposed, and a burr hole in a diameter of 2 mm was drilled on the right side of the skull at 2 mm posterior and 3 mm lateral to the bregma (Paxinos and Watson, 1986) to accommodate the probeholder. The field was frequently irrigated with physiological saline, and the dura mater was kept intact to prevent injury to the cortex. A laser-Doppler probe (probe 407-1; Perimed, Jarfalla, Sweden), held in the probeholder, was placed perpendicularly (avoiding large blood vessels).
MCAO was induced as described by Longa et al. (1989) and Belayev et al. (1996) and then modified by us. After a midline neck skin incision, the right common carotid artery and bifurcation were exposed, and the external carotid artery (ECA) and the internal carotid artery (ICA) were dissected free from surrounding nerves and fascia. The ECA were ligated distally, and a 4-0 nylon suture (its tip rounded by heating and coated with poly-L-lysine) was introduced into the lumen of the ICA through a small incision on the stump of the ECA. The suture was gently advanced into the ICA for 19 to 20 mm from the bifurcation of common carotid artery to block the origin of MCA, and the ipsilateral laser-Doppler signal decreased to approximately 20 to 30% of baseline. After 2 h of MCAO, reperfusion was achieved by withdrawal of the intraluminal suture from ECA. At 50 min of reperfusion, the laser-Doppler flow probe and catheter were removed. The trachea was extubated, and the neck incision was closed with silk sutures. The animal was allowed to awaken from anesthesia and survive for 24 h after ischemia.
Treatment Groups and Drug Administration. Rats were divided into six experimental groups randomly: three dl-PHPB-treated groups (1.3, 3.9, and 12.9 mg/kg), one dl-NBP-treated groups (10 mg/kg), one vehicle control group, and one sham-operated group. At 10 min after the onset of MCAO, drugs or vehicle were administered intravenously to rats in a volume of 1 ml/kg body weight.
Regional CBF Measurement. rCBF was measured continuously before and during the acute phase of ischemia and after reperfusion by means of a LDF. The rCBF value was calculated as the average value during a period of every 10 min. First, the rCBF was monitored for 10 min before MCAO to establish the baseline value (100%). Then, MCAO was induced by advancing the filament. After 2 h of occlusion, the filament was withdrawn. The changes in rCBF were expressed as a percentage of the baseline value.
Neurobehavioral Testing. After surgery, each animal's neurological function was evaluated at 24 h of reperfusion. Neurological deficit was graded on a score of 0 to 4 as described previously (Menzies et al., 1992; Belayev et al., 1996; Mokudai et al., 2000): 0, no observable deficit; 1, forelimb flexion; 2, forelimb flexion and decreased resistance to lateral push; 3, forelimb flexion, decreased resistance to lateral push, and unilateral circling; and 4, forelimb flexion and being unable or difficult to ambulate.
Infarct Assessment. At 24 h of reperfusion, the animals were anesthetized with trichloroacetaldehyde monohydrate (350 mg/kg i.p.) and decapitated. The brain was then rapidly removed, cut into six 2-mm-thick coronal sections (the last section was 4-mm-thick) by use of a rat brain matrix (RBM 4000C; ASI Instruments, Warren, MI), and stained with 4% 2,3,5-triphenyltetrazolium chloride (TTC; Sigma Co., St. Louis, MO) at 37°C for 30 min. Infarct area on each slice was determined by using digital imaging with a computerized image analyzer (SPOT 3.5 Biometrics software; Silicon Graphics, Inc., Mountain View, CA), and the infarct areas were calculated to obtain the infarct volumes per brain (in millimeters3). Infarct volumes were expressed as a percentage of the contralateral hemisphere volume by using an "indirect method" [area of intact contralateral (left) hemisphere minus area of intact regions of the ipsilateral (right) hemisphere] to compensate for edema formation in the ipsilateral hemisphere (Swanson et al., 1990; Mokudai et al., 2000).
 |
Conversion of dl-PHPB in Vitro. dl-PHPB was added into rat plasma at the final concentration of 6, 30, and 60 µg/ml and incubated for different periods (2, 5, 10, and 20 min). After the incubation, 200 µl of methanol was added into 100 µl of the plasma sample. Then, the samples were mixed by vortex for 20 min and centrifuged for 10 min at 8000 rpm. The supernatant was collected and directly injected into the high-performance liquid chromatography (Agilent 1100; Agilent, Palo Alto, CA) system. For quantification of dl-PHPB and dl-NBP, an Aichrom Bond-1 ODS column (particle size, 5 µm; 4.6 x 250 mm, pH 2
10; Abel Industries, Dumfries, VA) and the mobile phase comprised of methanol-0.1% phosphate buffer (50:50 for dl-PHPB, 65:45 for dl-NBP) were used. The flow rate was 1 ml/min. The wavelength for UV detection was 210 nm. The column temperature was kept at 25 ± 0.5°C. 4-Biphenylacetic acid (10 µl, 0.5 mg/ml) and diazepam (10 µl, 0.5 mg/ml) were used as the internal standard for quantification of dl-PHPB and dl-NBP, respectively.
Statistical Analysis. The results are expressed as mean ± S.E.M. Physiological data, neurological score, and infarct volume were statistically analyzed using one-way ANOVA followed by Dunnett's test for comparing the treatment groups and vehicle control group. The data from rCBF were analyzed by two-way ANOVA to detect differences between groups and over time. Results were considered to show a significant difference when the P value was less than 0.05.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
The rectal temperature in all groups was regularly maintained at a normal level (37°C) during surgical procedures (before, during ischemia, and 30 min of postischemia) under conditions of anesthesia and temperature-controlled system as shown in Table 1. At later reperfusion time points (12 and 24 h of postischemia) after rats recovered from anesthesia, the temperature definitely increased and reached approximately 39°C in the vehicle group as well as in drug-treated groups. However, there were no significant differences between them.
Neurological Assessment. Before MCAO, neurological score was zero in all animals. After MCAO, high-grade neurological deficits were present. The results are shown in Table 2. Compared with vehicle-treated rats (score, 3.2 ± 0.2), treatment with dl-PHPB significantly and dose-dependently improved the neurological score at 24 h after ischemia. At the highest dose, the efficacy of dl-PHPB (score, 1.8 ± 0.2) was similar to dl-NBP (score, 2.0 ± 0.2).
|
Infarct Volume And Protective Effect of dl-PHPB. Coronal sections of rat brain stained with TTC are shown in Fig. 2. Infarct volume was measured in animals after transient MCAO after treatment with dl-PHPB, dl-NBP, or vehicle (Fig. 3). At doses of 1.3, 3.9, and 12.9 mg/kg, dl-PHPB could dose-dependently reduce the infarct volume significantly from a vehicle control of 37.4 to 25.4, 17.4, and 13.7%, respectively (P < 0.01 versus vehicle control). The infarct volume in dl-NBP group (10 mg/kg) was 16.3%. This indicates that dl-PHPB shows the similar efficacy with dl-NBP in the reduction of infarct volume at the corresponding dose.
|
|
Effects of dl-PHPB on Regional CBF. Figure 4 shows the relative changes of rCBF with LDF during and after 2 h of MCAO. In all groups, MCA occlusion induced a similar immediate reduction of rCBF value to approximately 20 to 30% of the baseline level. During the ischemic period, the rCBF values in dl-PHPB groups and dl-NBP groups were significantly higher than that in vehicle group. Especially at high doses, dl-PHPB increased rCBF significantly from 20 min after administration and throughout the ischemic period. The potency of dl-PHPB was a little bit stronger than that of dl-NBP, but there was no significant difference between them at the corresponding dose. After recirculation, rCBF gradually recovered to approximately 70 to 80% of the baseline level. At the 50-min reperfusion, there were no significant differences between the vehicle and dl-PHPB groups. Two-way ANOVA of data, obtained after injection of dl-PHPB and dl-NBP, showed a significant effect of treatment (P < 0.05 versus vehicle control), but no effect of time during the ischemia.
|
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
), resulting in the frequent use of this model for evaluating neuroprotective agents (Muller et al., 1995; Engelhorn et al., 2004). Therefore, in present study, we used a rat model of 2-h intraluminal suture occlusion of MCA and 24-h reperfusion to produce transient focal cerebral ischemia.
As described above, the severity of damage after transient cerebral ischemia depends mainly on the duration of the ischemia and the degree of CBF reduction. For a given period of ischemia (2-h MCAO in our study), the infarct volume will be a function of CBF reduction. However, CBF in the ischemic core is usually strongly affected for quite a wide range of infarct sizes. Therefore, CBF in the periphery of the affected area (penumbra) can potentially indicate the extent of CBF alterations and, therefore, might give an estimation of the severity of ischemia (Memezawa et al., 1992,Memezawa et al., 1992; Soriano et al., 1997). Many kinds of methods are widely used for measuring CBF. All methods have strengths and weaknesses (Kramer et al., 1996). Compared with other methods, LDF provides a noninvasive and continuous measure of local CBF, increasing the ability to observe instantaneous changes in cerebral microcirculation. The changes of focal CBF after MCAO can be monitored by project zones of MCA in the surface of cerebra with LDF, which seems to give good estimations of CBF reductions. However, LDF did not record absolute blood flow, and it was very sensitive to an altered position of the LDF probe. In addition, under conditions of changed blood hematocrit or fluctuations of blood gases, LDF did not accurately measure CBF values (Kramer et al., 1996; Gu et al., 2003). Therefore, physiology parameters should be monitored at the same time.
dl-NBP was demonstrated as a useful drug for treatment of ischemic stroke in clinic studies. However, it was limited to use intravenously because of its property of hydrophobicity, and it was difficult in the treatment of serious patients. Therefore, dl-PHPB was designed as a prodrug of dl-NBP, and its properties have been greatly improved. In this study, it was shown that approximately 70% of dl-PHPB could convert into dl-NBP in 5 min when dl-PHPB was added into the plasma in vitro. A pharmacokinetic study in vivo also showed that dl-PHPB converted into dl-NBP quickly and completely after orally or intravenously administered. When given dl-PHPB intravenously to rat, it was difficult to determine in the plasma. However, after dl-PHPB injection for 1 min, dl-NBP was clearly found in rat plasma with quite high levels (J. Li, L. He, and X. Wang, unpublished data). The present results showed that intravenous treatment of dl-PHPB (1.3, 3.9, and 12.9 mg/kg) could dose-dependently reduce the infarct volume significantly. In addition, at the highest dose, dl-PHPB showed slightly higher efficacy in reducing infarct volume than dl-NBP, although there was no significant difference between the two compounds.
Neurobehavioral deficits were also observed 24 h after MCAO. It showed that dl-PHPB could also improve the behavioral deficits in a dose-dependent manner. The improvement effects of dl-PHPB observed were highly correlated with the reduction of infarct volumes at the same doses.
To determine whether the infarct-reducing effects of dl-PHPB are due to an increase in blood flow during ischemia, we measured rCBF in the penumbral region of cortex (2 mm posterior and 3 mm lateral to the bregma), which is also the project zone of MCA in the surface of cerebral. Our data showed that treatment with dl-PHPB could significantly improve rCBF during the period of occlusion, whereas the improving effect at the highest dose was far more potent than that at the middle or lowest dose. At the highest dose of dl-PHPB injection, CBF values increased from approximately 27 to 40% of the preischemia values (CBF values in the vehicle-treated group decreased from 25 to 15%), whereas CBF values in the middle-dose group only increased slightly from approximately 23 to 26%, just similar to the effect in the lowest dose (from approximately 29 to 24%). Compared with the dose-dependent results from the infarct and neurobehavioral assessments, such results indicate that the neuroprotective effect of higher doses of dl-PHPB observed in infarct and in the neurobehavioral test was mainly due to an improvement of blood flow during ischemia. However, at lower doses, the neuroprotection of dl-PHPB seemed to be a result of multiple mechanisms such as antioxidative and antiapoptosis effects that have been observed in our research, same as in dl-NBP (Dong and Feng, 2002; Chang and Wang, 2003). After the withdrawal of the intraluminal suture, rCBF in all groups gradually recovered. There was also a trend that the CBF values displayed after reperfusion in the treated groups was shown to be obviously higher than that in vehicle groups. Especially at high doses, treatment with dl-PHPB increased the CBF level by approximately 51.6% than the vehicle group at 30 min after reperfusion, although there were no significant differences between the vehicle and the treated group at the same individual time points.
Various physiological variables influence CBF, including arterial blood gases, cerebral autoregulation, metabolic rate through vasoneuronal coupling, and functional balance between the endothelium-dependent vasodilators and the endothelium-derived constrictors. One important mediator controlling basal CBF is nitric oxide (NO). Endothelium-derived NO plays a crucial role in maintenance of blood vessel caliber and, therefore, blood flow throughout the vasculature. It is also important in preventing thrombosis through inhibition of platelet adhesion, activation, and aggregation (Markus, 2004). Arachidonate metabolism also plays an important role in modulating CBF. Thromboxane A2 (TXA2) and prostaglandin I2 (PGI2) are major metabolites of cyclooxygenase activation in platelets and in endothelial cells, respectively. TXA2 is a potent platelet aggregating and vasoconstricting substance, whereas PGI2 is a powerful antiplatelet and vasodilator agent (Peng et al., 2004). Previous studies showed that dl-NBP could induce the activation of endothelial NO synthase and thus increase the production of NO (Yan and Feng, 1998). Furthermore, dl-NBP could decrease the production of TXA2 and increase the production of PGI2 in cerebral cortex cells and decrease the ratio of TXA2/PGI2 in brain tissue after MCAO in rat (Chong and Feng, 1997). Therefore, such activities might be also involved in the rCBF improvement effects of dl-PHPB.
In conclusion, dl-PHPB significantly reduces infarct volume and improves neurobehavioral deficits in rat model of transient focal cerebral ischemia. Such effects may be partly due to the increase of rCBF. In addition, multiple mechanisms for neuroprotection might be involved in the effects of dl-PHPB. Therefore, further studies are needed to completely elucidate the mechanism accounting for the protective effects of dl-PHPB on cerebral ischemia.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: CBF, cerebral blood flow; MCAO, middle cerebral artery occlusion; dl-PHPB, 2-(1-hydroxypentyl)-benzoate; dl-NBP, 3-n-butylphthalide; MABP, mean arterial blood pressure; LDF, laser-doppler flowmetry; rCBF, regional cerebral blood flow; ECA, external carotid artery; ICA, internal carotid artery; TTC, 2,3,5-triphenyltetrazolium chloride; ANOVA, analysis of variance; MCA, middle cerebral artery; NO, nitric oxide; TXA2, thromboxane A2; PGI2, prostaglandin I2.
Address correspondence to: Xiao-Liang Wang, Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nong Tan Street, Beijing 100050, China. E-mail: wangxl{at}imm.ac.cn
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Belayev L, Alonso OF, Busto R, Zhao W, and Ginsberg MD (1996) Middle cerebral artery occlusion in the rat by intraluminal suture: neurological and pathological evaluation of an improved model. Stroke 27: 1616–1622.
Bolander HG, Persson L, Hillered L, d'Argy R, Ponten U, and Olsson Y (1989) Regional cerebral blood flow and histopathological changes after middle cerebral artery occlusion in rats. Stroke 20: 930–937.
Chang Q and Wang XL (2003) Effects of chiral 3-n-butylphthalide on neuronal apoptosis induced by transient focal cerebral ischemia in rats. Acta Pharmacol Sin 24: 796–804.[Medline]
Chong ZZ and Feng YP (1997) Effects of dl-3-n-butylphthalide on production of TXB2 and 6-keto-PGF1 alpha in rat brain during focal cerebral ischemia and reperfusion. Acta Pharmacol Sin 18: 505–508.
Dirnagl U, Iadecola C, and Moskowitz MA (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391–397.[CrossRef][Medline]
Dirnagl U, Kaplan B, Jacewicz M, and Pulsinelli W (1989) Continuous measure of cerebral cortical blood flow by laser-Doppler flowmetry in a rat stroke model. J Cereb Blood Flow Metab 9: 589–596.[Medline]
Dong GX and Feng YP (2002) Effects of NBP on ATPase and anti-oxidant enzymes activities and lipid peroxidation in transient focal cerebral ischemic rats. Acta Acad Med Sin 24: 93–97.
Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, and Schulz R (2004). The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 24: 467–474.[CrossRef][Medline]
Feng YP (1999) Pathophysiology of ischemic stroke and status of drug intervention. Acta Pharmacol Sin 34: 72–78.
Gu WG, Jiang W, and Wester P (2003) Real-time cortical cerebral blood flow follow-up in conscious, freely moving rats by laser Doppler flowmetry. Methods 30: 172–177.[Medline]
Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, et al. (2003) Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 34: 109–137.
Hou ST and MacManus JP (2002) Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol 221: 93–147.[Medline]
Jorgensen MB and Diemer NH (1982) Selective neuron loss after cerebral ischemia in the rat: possible role of transmitter glutamate. Acta Neurol Scand 66: 536–546.[Medline]
Kramer MS, Vinall PE, Katolik LI, and Simeone FA (1996) Comparison of cerebral blood flow measured by laser-Doppler flowmetry and hydrogen clearance in cats after cerebral insult and hypervolemic hemodilution. Neurosurgery 38: 355–361.[CrossRef][Medline]
Longa EZ, Weinstein PR, Carlson S, and Cummins R (1989) Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20: 84–91.
Mahajan SK, Kashyap R, Sood BR, Jaret P, Mokta J, Kaushik NK, and Prashar BS (2004) Stroke at moderate altitude. J Assoc Physicians India 52: 699–702.[Medline]
Markus HS (2004) Cerebral perfusion and stroke. J Neurol Neurosurg Psychia 75: 353–361.[CrossRef]
Memezawa H, Minamisawa H, Smith ML, and Siesjo BK (1992) Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp Brain Res 89: 67–78.[CrossRef][Medline]
Memezawa H, Smith ML, and Siesjo BK (1992) Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke 23: 552–559.
Menzies SA, Hoff JT, and Betz AL (1992) Middle cerebral artery occlusion in rats: a neurological and pathological evaluation of a reproducible model. Neurosurgery 31: 100–106.[Medline]
Mokudai T, Ayoub IA, Sakakibara Y, Lee EJ, Ogilvy CS, and Maynard KI (2000) Delayed treatment with nicotinamide (Vitamin B(3)) improves neurological outcome and reduces infarct volume after transient focal cerebral ischemia in Wistar rats. Stroke 31: 1679–1685.
Muller TB, Haraldseth O, Jones RA, Sebastiani G, Lindboe CF, Unsgard G, and Oksendal AN (1995) Perfusion and diffusion-weighted MR imaging for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke 26: 1453–1458.
Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, 2nd ed, Academic Press, New York.
Peng Y, Zeng XG, Feng YP, and Wang XL (2004) Antiplatelet and antithrombotic activity of L-3-butylphthalide in rats. J Cardiovasc Pharmacol 43: 876–881.[CrossRef][Medline]
Silvestrelli G, Corea F, Paciaroni M, Milia P, Palmerini F, Parnetti L, and Gallai V (2002) The Perugia hospital-based Stroke Registry: report of the 2nd year. Clin Exp Hypertens 24: 485–491.[Medline]
Soriano MA, Sanz O, Ferrer I, and Planas AM (1997) Cortical infarct volume is dependent on the ischemic reduction of perifocal cerebral blood flow in a three-vessel intraluminal MCA occlusion/reperfusion in the rat. Brain Res 747: 273–278.[CrossRef][Medline]
Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, and Sharp FR (1990) A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10: 290–293.[Medline]
Takagi K, Zhao W, Busto R, and Ginsberg M (1995) Local hemodynamic changes during transient middle cerebral artery occlusion and recirculation in the rat: a [14C]-iodoantipyrine autoradiographic study. Brain Res 691: 160–168.[CrossRef][Medline]
Xu HL and Feng YP (2000) Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta Pharmacol Sin 21: 433–438.[Medline]
Xu HL and Feng YP (2001) Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats. Acta Pharmacol Sin 36: 329–333.
Yamori Y, Horie R, Handa H, Sato M, and Fukase M (1976) Pathogenetic similarity of strokes in stroke-prone spontaneously hypertensive rats and humans. Stroke 7: 46–53.
Yan CH and Feng YP (1998) Effects of d-3-n-butylphthalide and l-3-n-butylphthalide on extracellular NO level and intracellular cGMP level in primary cultured rat cortical neurons. Acta Pharmacol Sin 33: 418–423.
Yan CH, Feng YP, and Zhang JT (1998) Effect of dl-3-n-butylphthalide on striatum cerebral blood flow in normal and middle cerebral artery occlusion rats. Chin J Pharmacol Toxicol 12: 36–39.
Yang JH, Wang XL, Xu ZB, and Peng Y (2002) inventors, Institute of Materia Medica, Chinese Academy of Medical Sciences, assignee. Novel salts of 2-(
-hydroxypentyl) benzoic acid, the methods for preparation and the application of these salts. Patent PCT/CN02/00320. 2002 May 9.
Zhang Y, Wang L, Zhang LY, and Wang XL (2004) Effects of 2-(1-hydroxypentyl)-benzoate on platelet aggregation and thrombus formation in rats. Drug Dev Res 63: 174–180.[CrossRef]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
